ad image

Solid Tumors

1 / 1
Inceptor Bio
Announcement

Inceptor Bio and GRIT Bio Cooperate to Advance IB-T101, a Next-Generation Solid Tumor CAR-T Utilizing the OUTLAST™ Platform

Inceptor Bio

PR-12-24-NI-142Dec 18, 2024
Engineering Immune Cells to Realize the Promise of Cancer Cell Therapies
Cell Therapy

Engineering Immune Cells to Realize the Promise of Cancer Cell Therapies

Beau Webber, Ph.D.

Luminary Therapeutics

PAO-08-23-CL-04Sep 05, 2023
CytoDyn Takes Steps towards a Brighter Future
Therapeutic Candidate

CytoDyn Takes Steps towards a Brighter Future

Cyrus Arman, Ph.D.

CytoDyn

PAO-02-23-CL-04Feb 06, 2023
Umoja Biopharma
CAR-T and iPSC Platform Technologies

Umoja Biopharma Presents New Preclinical Data on its Integrated In Vivo CAR-T and Engineered iPSC Platform Technologies at the SITC 37th Annual Meeting

Umoja Biopharma

PR-M11-22-06Nov 11, 2022
Fighting Solid Tumors by Targeting Neoantigens in a Personalized Manner
Cell Therapy

Fighting Solid Tumors by Targeting Neoantigens in a Personalized Manner

Mark Shlomchik, M.D., Ph.D.

BlueSphere Bio

PAO-06-022-CL-03Jun 06, 2022
Tegmine Therapeutics
Oncology Collaboration

Tegmine Therapeutics Announces Collaboration with Alloy Therapeutics to Advance Solid Tumor Treatment

Tegmine Therapeutics

PR-M04-22-03Apr 06, 2022
Anixa Biosciences
Phase I Trial

Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase I Trial at Moffitt Cancer Center

Anixa Biosciences

PR-M03-22-17Mar 30, 2022
Bayer
Strategic Collaboration

Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors

Bayer

PR-M11-20-030Dec 10, 2020
BioLineRx
Clinical Study

BioLineRx Initiates Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors

BioLineRx

PR-M08-18-NI-030Aug 08, 2018
1 / 1